Next Article in Journal
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model
Previous Article in Journal
Current Development of Therapeutic Vaccines in Lung Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 13
Issue 2
10.3390/vaccines13020186
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Vaccines 2023, 11(7), 1224.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Patel et al. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines. Vaccines 2023, 11, 1224

by
Nisarg Patel
†,
Zach Davis
‡,
Carl Hofmann
,
Josef Vlasak
,
John W. Loughney
,
Pete DePhillips
and
Malini Mukherjee
*
Analytical Research & Development, Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
*
Author to whom correspondence should be addressed.
†
Current address: Technical Development, Spark Therapeutics, 3025 Market Street, Philadelphia, PA 19104, USA.
‡
Current address: Analytical Outsourcing, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA.
Vaccines 2025, 13(2), 186; https://doi.org/10.3390/vaccines13020186
Submission received: 22 January 2025 / Accepted: 24 January 2025 / Published: 14 February 2025
Browse Figure
Versions Notes
The authors would like to make the following corrections to this published paper [1].
In the original publication, there was a mistake in Figure 1H,I as these images were accidentally duplicated. There was also a mistake in the cell line name in Figure 1F. The corrected Figure 1 is attached below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Patel, N.; Davis, Z.; Hofmann, C.; Vlasak, J.; Loughney, J.W.; DePhillips, P.; Mukherjee, M. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines. Vaccines 2023, 11, 1224. [Google Scholar] [CrossRef]
Vaccines 13 00186 g001
Figure 1. LNP transfection curves across varying cell lines indicate variable levels of transfection, which improve with the addition of ApoE during transfection. (A) RSV-F protein expression efficiency in Vero, HeLA, HEp-2, A549, CaCo-2 and HepG2 cells was measured by counting percentage of cells positive for RSV-F protein. All cells were transfected for 16 ± 2 h with titration of LNPs starting with 200 ng dose of mRNA in media with 2% FBS. Data were fit using variable slope-four parameter logistics regression (4-PL) model in GraphPad Prism software (version: 6.0). (B–G) RSV-F protein expression efficiency following transfection with LNPs in media + 2%FBS, and media + 2%FBS supplemented with ApoE at 4 ug/mL. Hill-slope values [Y = Bottom + (Top − Bottom)/(1 + 10^((LogEC50-X) × Hill-slope)] from 4-PL regression are given for curves obtained with FBS supplemented with ApoE. (B) HeLa cells. (C) Vero cells. (D) Hep-2 cells. (E) CaCo-2 cells. (F) A549 cells. (G) HepG2 cells. (H) Representative immunofluorescence images of HepG2, Vero and A549 cells without ApoE and (I) with ApoE shown at 72 (top row) and 200 ng/mL (bottom row) of mRNA dose representing the bottom and top of the dose response curve, respectively.
Figure 1. LNP transfection curves across varying cell lines indicate variable levels of transfection, which improve with the addition of ApoE during transfection. (A) RSV-F protein expression efficiency in Vero, HeLA, HEp-2, A549, CaCo-2 and HepG2 cells was measured by counting percentage of cells positive for RSV-F protein. All cells were transfected for 16 ± 2 h with titration of LNPs starting with 200 ng dose of mRNA in media with 2% FBS. Data were fit using variable slope-four parameter logistics regression (4-PL) model in GraphPad Prism software (version: 6.0). (B–G) RSV-F protein expression efficiency following transfection with LNPs in media + 2%FBS, and media + 2%FBS supplemented with ApoE at 4 ug/mL. Hill-slope values [Y = Bottom + (Top − Bottom)/(1 + 10^((LogEC50-X) × Hill-slope)] from 4-PL regression are given for curves obtained with FBS supplemented with ApoE. (B) HeLa cells. (C) Vero cells. (D) Hep-2 cells. (E) CaCo-2 cells. (F) A549 cells. (G) HepG2 cells. (H) Representative immunofluorescence images of HepG2, Vero and A549 cells without ApoE and (I) with ApoE shown at 72 (top row) and 200 ng/mL (bottom row) of mRNA dose representing the bottom and top of the dose response curve, respectively.
Vaccines 13 00186 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Patel, N.; Davis, Z.; Hofmann, C.; Vlasak, J.; Loughney, J.W.; DePhillips, P.; Mukherjee, M. Correction: Patel et al. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines. Vaccines 2023, 11, 1224. Vaccines 2025, 13, 186. https://doi.org/10.3390/vaccines13020186

AMA Style

Patel N, Davis Z, Hofmann C, Vlasak J, Loughney JW, DePhillips P, Mukherjee M. Correction: Patel et al. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines. Vaccines 2023, 11, 1224. Vaccines. 2025; 13(2):186. https://doi.org/10.3390/vaccines13020186

Chicago/Turabian Style

Patel, Nisarg, Zach Davis, Carl Hofmann, Josef Vlasak, John W. Loughney, Pete DePhillips, and Malini Mukherjee. 2025. "Correction: Patel et al. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines. Vaccines 2023, 11, 1224" Vaccines 13, no. 2: 186. https://doi.org/10.3390/vaccines13020186

APA Style

Patel, N., Davis, Z., Hofmann, C., Vlasak, J., Loughney, J. W., DePhillips, P., & Mukherjee, M. (2025). Correction: Patel et al. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines. Vaccines 2023, 11, 1224. Vaccines, 13(2), 186. https://doi.org/10.3390/vaccines13020186

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop